Roivant Sciences sank -4.9% today, compared to the S&P 500's day change of -1.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Roivant Sciences has moved 72.9% over the last year, and the S&P 500 logged a change of -8.9%
-
ROIV has an average analyst rating of buy and is -49.24% away from its mean target price of $13.86 per share
-
Its trailing earnings per share (EPS) is $-1.8
-
Roivant Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -3.9 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $-1.35 and its forward P/E ratio is -5.2
-
The company has a Price to Book (P/B) ratio of 5.3 in contrast to the S&P 500's average ratio of 2.95
-
Roivant Sciences is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
The company has a free cash flow of $-571,135,616.00, which refers to the total sum of all its inflows and outflows of cash over the last quarter
-
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.